Leave it to conventional wisdom and pharmaceutical companies would continue to buy biotech companies as they search for much needed growth. But as biotechnology companies go after more mass market diseases would they in-turn buy their pharmaceutical brethren? While nobody is saying it will happen tomorrow, analysts said biotech companies, usually the prey, could eventually become the predator. “Pharmaceutical companies are becoming like biotech companies and biotech companies are becoming like pharmaceutical companies,” said Geoff Porges, a biotech analyst at Sanford Bernstein. “It’s much harder to distinguish what a biotech and pharmaceutical company is.” Rewind a couple of decades and there was a clear distinction between biotech and pharmaceutical companies. Biotechs, back then, were considered unproven companies that were...
[read full story]
Your Web Site
